GIVE REGULARLY: FUND LIFE-SAVING OVARIAN CANCER RESEARCH
When you give regularly, be it weekly, fortnightly, monthly, you become a driving force behind life-saving ovarian cancer research.
As Australia’s leading independent funder of ovarian cancer research, the Ovarian Cancer Research Foundation (OCRF) relies entirely on people like you to keep research moving.
For too long, ovarian cancer has been underfunded and overlooked. But thanks to committed regular givers, we’re finding and funding the most promising research projects in labs across Australia and beyond.
Your generosity gives researchers the reliable, ongoing funding they need to make progress faster: to detect ovarian cancer earlier, treat it more effectively, and one day, prevent it altogether.
You’re not just funding research—you’re accelerating the progress that women with ovarian cancer urgently need.
BECOME A REGULAR DONOR
Select how often and how much you would like to donate. Your contribution provides the lifeblood of research funding.
This is more than a donation. This is how we will overcome ovarian cancer – together.
Secure Payment
JOIN US
Join an exceptional community of Australians who believe in a healthy vital future for all those affected by ovarian cancer and:
- Know that you’re driving progress and enabling tomorrow’s research discoveries.
- See your impact in action and follow updates on the incredible impact you are having.
- Receive regular news and updates in our monthly O-Newsletter
- Receive invitations to a range of events and other offers from OCRF and our partners
- Receive a consolidated tax statement at the end of each financial year.
FUND WORLD LEADING OVARIAN CANCER RESEARCHERS
Researchers across Australia are working on projects to address early detection, as well as developing new and more effective treatments for ovarian cancer. They need your ongoing support to access the funding that will keep their research moving.
One of these is Professor Salomon Gallo.
Over the past seven years, his team at the University of Queensland has developed the OCRF-7 ovarian cancer test, named in recognition of the OCRF’s previous funding. The test, which involves a combination of biomarkers, has outperformed the CA-125 biomarker, which is currently clinically used to signal the potential presence of ovarian cancer. A previous OCRF-7 study suggested that the OCRF-7 has over 90% accuracy in identifying stage I and II ovarian cancer in a 465-sample case-control cohort, while CA-125 identified ovarian cancer in approximately 60% in the same patients. Thanks to ongoing funding from supporters like you, the OCRF is currently funding a project that allows the team to validate the OCRF-7’s diagnostic accuracy in larger and more complex sample groups, and there are plans to move into clinical trials within the year.
THIS IS MORE THAN A DONATION.
Professor Salomon Gallo’s project is one of 22 projects currently supported by OCRF grants, investigating early detection, better treatments and reducing recurrence, with the aim of saving lives.
Thank you.
Thank you for considering a regular donation. For too long, ovarian cancer has ranked as the most lethal gynaecological cancer, taking the lives of more than half of the women and girls who receive this feared diagnosis, within five years.
But there is hope - Research can change this, and research can only happen with support from passionate people like you.
